STAT News published a subscriber-only item dated Sept. 17, 2026, reporting the emergence of a new immunology company named North Immunology. The visible portion of the article identifies the company’s development focus as a long-acting antibody aimed at treating atopic dermatitis. The piece is authored by Adam Feuerstein and appears in STAT’s biotech and drug-development coverage. The full article content is behind the STAT+ paywall; only an excerpt and metadata are publicly accessible.
According to the accessible excerpt, the idea to start the company originated with Mohit Gupta, described as an analyst who works for Dan Schneeberger at Adar1 Capital. Gupta reportedly presented the pitch to Schneeberger in Schneeberger’s Austin, Texas, office roughly two years prior to publication. The public text frames this pitch as the initiating event that led to formation of North Immunology.
The article explicitly states that North Immunology is pursuing a better, long-acting antibody treatment for atopic dermatitis. A captioned image included with the report reiterates that the company is developing a long-acting antibody for this indication. No additional technical, preclinical, or clinical details are provided in the excerpt about the antibody’s target, mechanism of action, formulation, delivery approach, or evidence to support the program.
The accessible portion highlights a contextual contrast: Dan Schneeberger’s primary role at Adar1 Capital is investing in biotech companies that already exist, not founding companies himself. The story frames the creation of North Immunology as notable partly because it arose from an investment analyst’s internal pitch and because it represents a move from a hedge-fund investment role toward company creation. Beyond that framing, information about the fund’s level of involvement, financial commitment, governance, board composition, or whether Adar1 Capital formally sponsors or incubates North Immunology is not reported in the public excerpt.
The visible content identifies Adam Feuerstein as the author and lists his roles and contact information as provided by STAT. It also notes that the piece first appeared in Adam’s Biotech Scorecard, which is a STAT+ subscriber newsletter. Readers are informed that the remainder of the story requires a STAT+ subscription or login to access. The article carries site navigation, related links, and standard STAT News imagery and metadata but omits the substantive remainder of the reporting from the public view.
The publicly accessible excerpt does not report many items that would be clinically or operationally relevant. Specifically, the excerpt does not include:
Because the STAT News article is a STAT+ subscriber piece and the remainder of the reporting is behind a paywall, the source does not provide these details in the publicly available excerpt. Readers seeking more comprehensive information will need to access the full STAT+ article.
The available report establishes that North Immunology was born from an internal pitch by an analyst at a hedge-fund–affiliated investment firm and that the company is focused on creating a long-acting antibody for atopic dermatitis. It underscores the unusual origin—coming from within a hedge fund environment where the principal’s usual role is investment rather than company formation. Important scientific, clinical, financial, and operational details are not included in the accessible excerpt; the full story requires STAT+ subscription access and thus was not available in the source material provided.